Leukocyte Ig-like receptors (LILRs)/Ig-like transcripts (ILTs) are expressed on innate and adaptive immune cells and maintain immune homeostasis. LILRs consist of activating and inhibitory-type receptors that regulate adequate cellular functions. LILRs were firstly identified as MHC class I receptors, therefore expression and/or polymorphisms of LILRs are reported to associate with autoimmune disorders and transplant rejection; however, recent accumulating evidences have revealed that LILRs recognize with diverse ligands including bacteria and virus. In addition, inhibitory LILRB2 (ILT4) and murine relative paired Ig-like receptor (PIR)-B are expressed on neuron and is involved in the dysregulation of central nervous system via interaction with neuronal ligands including amyloid b-protein. In this review, we summarize recent discoveries on the functions of inhibitory MHC class I receptors, and discuss their regulatory roles in immune responses and neural functions.
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For maintaining homeostasis, various receptors on the cell surface act as sensors to protect the body from antigen and to respond to changes in the environment.
When receptors recognize ligand and input signals at the surface, appropriate responses, such as gene transcription, are induced. To recognize various signaling molecules specifically, most receptors have immunoglobulin (Ig)-like domains. These Ig superfamily (IgSF) proteins play important roles in the recognition of antigens, costimulatory proteins, adhesion molecules and immunomodulatory receptors.
The CD85 family has been termed leukocyte Ig-like receptors (LILRs) and is an IgSF known to regulate the immune function. These receptors are expressed on innate and adaptive immune cells and regulate cell functions through signal transduction, both positively and negatively. LILRs include activating and inhibitory type receptors that balance cellular responses.
Major histocompatibility complex (MHC) class I consists of a heavy (a) chain associated with b2-microglobulin (b2m). The MHC class I/antigen complex is recognized by T cell receptors (TCRs) on CD8 T cells, and CD8 binds to MHC class I simultaneously. The formation of the TCR-antigen/MHC class I-CD8 complex is critical for CD8 T cell development and antigen presentation to CD8 T cells.
LILRs are identified as MHC class I receptors on myeloid cells and B cells. Previous studies have revealed that inhibitory LILRs interact with self MHC class I in cis and constitutively induces self-regulatory signaling. Recently, LILRs are also discovered to be expressed in the central nervous system (CNS) and regulate neuronal functions, axonal regeneration and neurodegeneration via binding to neuronal ligands. Therefore, dysfunction or imbalance in LILR signaling is thought to provoke not only autoimmune disorders but also neuronal disorders.
The neuronal expression of many immune receptors and new ligands has been reported in recent years, and attention has been focused on the physiological functions of the immune molecules in the CNS. However, because the CNS is normally sequestered from the peripheral immune system by the blood brain barrier, little attention has been paid to immune receptors in the CNS.
In this review, we summarize the structure, signaling mechanisms and ligands of LILRs and their murine orthologues (paired Ig-like receptors; PIRs) and discuss the role of these receptors in immunological and neurological functions.
Ig-like receptors (KIRs). LILR families typically have four Ig-like domains in their extracellular region, a transmembrane domain and a cytoplasmic tail ( Fig. 1)  (1, 2) . LILRs are divided into two types of receptor, activating-type receptors, LILRA1A6 (also termed LIR6, ILT1, ILT6, ILT7, ILT11 and ILT8, respectively) and inhibitory-type receptors, LILRB1B5 (also termed ILT2, ILT4, ILT5, ILT3 and LIR8, respectively). LILRA5 and LILRB4 have only two Ig-like domains, and alternative splicing of LILRA1 also produces a twodomain isoform. LILRA3 does not contain a transmenbrane region and is produced as a soluble, secreted form. Murine orthologue, PIRs are located on murine chromosome 7 and composed of two types, activating PIR-A and inhibitory PIR-B (3).
Activating LILRAs and PIR-A have a short cytoplasmic tail and an arginine residue in the transmembrane domain, which is associated with immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor proteins, such as Fc receptor g-chain (FcRg) (Fig. 2) . The ITAM domain is defined by a conserved sequence such as Yxx(L/I)x6-8Yxx(L/I). The binding of ligands to LILRAs and PIR-A induces the phosphorylation of the tyrosine residues of the ITAM motif by Src family tyrosine kinase. The phosphorylated ITAM domain then recruits Syk tyrosine kinase and activates downstream tyrosine kinases.
Inhibitory receptors (LILRBs) and PIR-B, in contrast, have either an immunoreceptor tyrosine-based inhibitory motif (ITIM) or ITIM-like sequences in their cytoplasmic region (Fig. 2) . The ITIM domains is defined by a conserved sequence such as (I/V/L/ S)xYxx(I/V/L). Upon co-ligation of these receptors with their ligands, the tyrosine residue of the ITIMs is phosphorylated by Src family kinases, and provides the docking sites for the recruitment of tyrosine phosphatases, Src homology 2-containing tyrosine phosphatase 1 or 2 (SHP-1 or SHP-2). These phosphatases subsequently dephosphorylate tyrosine kinases, such as Syk or Btk, resulting in the inhibition of the signaling cascade. Murine PIR-B is constitutively phosphorylated and associated with SHP-1 because PIR-B associates with MHC class I on the same cell surface (cis-interaction) (Fig. 2) .
LILRs are expressed on various myelomonocytic cells and on lymphoid cells ( breast cancer and human non-small cell lung cancer (1012) .
Surprisingly, LILRB2 is also expressed on haematopoietic stem cells (HSCs) and interact with angiopoietin-like protein (ANGPTL) 2 that is expressed in many tissues. LILRB2-ANGPTL2 interaction induces leukemia growth in addition to HSCs (13) . It is postulated that SHP1/2 function as a phosphatase-independent scaffold protein in LILRB2-expressing cancer (1).
Ligands
Classical MHC (HLA) class I Human LILRs are categorized into two groups based on sequence similarity. One group consists of LILRB1-B2 and LILRA1-A3. Except LILRA2, this group of LILRs bind to MHC class I, human leukocyte antigen (HLA)-A, HLA-B and HLA-C. Activating LILRAs bind to HLA class I with lower affinity than inhibitory LILRB1 and B2 ( Fig. 1) (14, 15) .
The other group consists of LILRB3-B5 and LILRA4-A6. LILRB5 has been shown to bind to b2m free heavy chain (FHC) of HLA-B27 (16) . LILRA4 is reported to bind to bone marrow stromal cell antigen 2 (BST2) (17) . Recently, LILRA2 is shown to recognize Igs cleaved by proteases secreted from bacteria such as Mycoplasma hyorhinis and Legionella pneumophila (18) (Fig. 1) . In contrast, ligands of LILRA5, A6 and LILRB4 have not been identified. The murine LILRB orthologue PIR-B binds to various members of murine MHC class I, H-2K, D and L with similar affinities (3).
LILRB1, B2 and murine PIR-B recognizes a broad range of MHC class I on same cell surface in cis (Fig. 2) (6, 7, 19) . Furthermore, the molecular interaction between LILRB and MHC class I has been well analyzed. TCRs and KIRs recognize the a1 and a2 domains of MHC class I heavy chain, whereas the membrane distal domain 1 (D1) of the LILRB1 and B2 interacts with the non-polymorphic a3 domain, and D2 associates with b2m of HLA class I molecules. Therefore, LILRB1 and B2 recognize MHC class I without allele specificity. In contrast, TCRs and KIRs binds to MHC class I with allele specificity. Since CD8 mainly interacts with a3 domain of MHC class I, both LILRB1 and B2 compete with CD8 for binding to MHC class I (20) . Thus, these LILRBs can suppress CD8 T cell activation by binding to MHC class I.
Non-classical MHC class I
In addition to binding classical HLA class I, LILRB1 and B2 also bind the non-classical HLA molecules HLA-E, F and G. LILRB2 also recognizes native CD1d to block the loading of lipid antigen onto CD1d ( Fig. 1) (21) .
HLA-G is firstly identified to be expressed on placenta trophoblasts and thymic epithelial cells. HLA-G expression is also induced on lymphocytes, myeloid cells and cancer cells. It was shown that LILRBs/ HLA-G interaction suppresses B-cell lymphoma proliferation (22, 23) . There are seven isoforms in HLA-G, membrane-bound HLA-G1G4 and soluble HLA-G5-G7. LILRB1 or B2 interact with disulfide-linked HLA-G1 dimer with a very high Kd compared with the HLA-G1 monomer, and the HLA-G1 dimer induces enhanced LILRB1 and B2-mediated inhibitory signaling (24) . LILRB1 and B2 show a different MHC class I recognition pattern, although they show high sequence homology. LILRB2, but not LILRB1, binds FHCs of HLA-G and HLA-Cw4 (25) . In addition, LILRB1 does not interact with HLA-G2, which is one of truncated isoforms constituted by a1 and a3 domain (26) , suggesting that LILRB1 mainly interacts with b2m. HLA-B27, whose allele has been closely associated with spondyloarthropathy, is occasionally expressed in an FHC form. As with HLA-G and HLA-Cw4, LILRB2, but not LILRB1, binds to the FHCs of HLA-B27 (27) .
Pathogens
Recent reports have shown that PIR-B and LILRBs bind to pathogens (Fig. 1) , suggesting the involvement of these receptors in innate immunity. Staphylococcus aureus is a leading cause of bacterial infections in developed countries, and neutrophils are known to be a major player in defense against this pathogen. However, S. aureus may employ LILRB3 on neutrophils to attenuate the immunoresponse, as this pathogen can specifically bind to LILRB3 and LILRB1 in vitro (28) . PIR-B also directly interacts with S. aureus, and PIR-B-deficient (Pirb -/-) mice rapidly eliminate S. aureus in vivo, suggesting that S. aureus attenuates neutrophil functions via binding to PIR-B (29). In contrast, Pirb -/-mice fail to eliminate Salmonella typhimurium and exhibit higher mortality (30) . It has been reported that Escherichia coli and Helicobacter pylori also bind to LILRB1 and/or PIR-B. LILRB1 and B2 recognize the human cytomegalovirus (HCMV) HLA class I homolog UL18, which inhibits the NK response (31) . Although LILRB2 binds to UL18 with a similar weak micromolar-order Kd to classical MHC class I, LILRB1 shows a significantly higher affinity (nanomolar-order Kd) to UL18 than other MHC class I members (32) . Therefore, the high affinity binding of UL18 to inhibitory MHC class I receptors might be an immune evasion mechanism of HCMV.
Dengue virus also uses LILRB1 to escape the antiviral response. Isolated E protein that constitutes the virus surface can bind to LILRB1 (33) . Recent studies have also suggested that human immunodeficiency virus (HIV) may escape from neutrophil extracellular traps by neutrophils via LILRB2 inhibitory signals (34) . HIV-derived peptides bind to HLA class I enhance the association with LILRB2. In these manners, inhibitory LILRBs and/or PIR-B are exploited to attenuate the host defense by some bacteria and viruses.
Functions in Immune Disorders
Inhibitory LILRBs and PIR-B repress activation of immune cells upon interaction with ligands, indicating that LILRBs and PIR-B function as immune checkpoints such as PD-1. Enhanced expression or secretion of LILRs has been reported in several autoimmune diseases, and suggesting these LILRs may be used as a diagnostic and/or pathogenic molecular marker.
Systemic lupus erythematosus (SLE) is characterized by production of anti-double strand (ds) DNA autoantibody from deregulated B cell/Plasma cell. Enhanced expression of LILRB4 on pathogenic plasmablasts and plasma cells, which actively transcribes anti-dsDNA immunoglobulin variable heavy chain, has been demonstrated in SLE patients (35) . On the other hand, soluble LILRA3 may also be involved in chronic inflammatory disease e.g. multiple sclerosis (MS) and rheumatoid arthritis (RA). The serum levels of LILRA3 in MS and RA patients are increased although genetic deletion is not associated with MS susceptibility (36, 37) . It was shown that LILRB1 polymorphisms affect the expression level on cell surface, and association with RA (38) . LILRA2 and LILRB2 and B3 expressions are found in synovial tissue from patients with active RA, and are reduced by treatment with anti-rheumatic drugs (39) .
Non-classical HLA-G and G2 dimer also bind to PIR-B, and subcutaneously administration of HLA-G2 induces immunosuppressive effect in collageninduced arthritis mice, suggesting HLA-G2 might be a useful for the treatment of RA (40, 41) .
In mice, deletion of PIR-B shows hyper-responses to various stimulations (Table I) . BCR ligation in splenic B cells or IgE-stimulation in mast cells from Pirb -/-mice enhanced antibody production or anaphylactic response, respectively (7). Immunization with thymus-dependent antigens induces T helper type 2 (Th2)-prone immune responses in Pirb -/-mice (5). Moreover, Pirb -/-mice, which transferred allogeneic splenocytes, show exacerbated graft-versus host disease (GVHD) (19) . Thus, PIR-B negatively regulates immune responses, and is critical for B cell suppression, DC maturation and for balancing Th1 and Th2 immune responses.
PIR-B is also involved in allergic airway inflammation. Eosinophilia is critically regulated by IL-5, which plays an important role in differentiation of eosinophils. IL-5 activity in eosinophils is regulated by PIRs via binding to MHC class I. PIR-B is required for development of eosinophils and suppresses proapoptotic signals by PIR-A. Pirb -/-mice exhibit increased bone marrow eosinophil apoptosis and decreased peripheral blood and tissue eosinophilia after mucosal aeroallergen challenge (42) .
Functions in Central Nervous System
LILRs and PIRs, the receptors originally thought to function exclusively in the immune system, have now also been found to be expressed by neurons, present in neuronal growth cones and associated with synapses. It was recently reported that MHC class I is involved in neurogenesis and neurodegeneration. LILRs are also considered to regulate neuronal functions, such as axonal regeneration and synaptic plasticity.
Spinal cord injury
Spinal cord injury is a complicated pathological process. In contrast to the peripheral nervous system, axons cannot regenerate readily after injury in the adult mammalian CNS. Many signaling pathways are involved in the repair or regeneration of neurons and axons, and several unfavorable inhibitor molecules, such as myelin-associated inhibitors (MAIs), are present in the CNS. Oligodendrocytes have a pivotal role in the formation of myelin sheath around the axon. Simultaneously, oligodendrocytes express MAIs including Nogo and negatively regulate an excessive axonal growth though interaction with Nogo receptor (NgR) on neuron (Fig. 3) . In particular, the C-terminal (43, 44) . These MAIs also bind to LILRB1, B2 and PIR-B and transduce inhibitory signals in the neuron ( Fig. 3 ) (45, 46) . Defects of NgR and PIR-B in neurons completely restored the axonal regeneration ability after injury. Nogo binds to LILRBs/PIR-B and induces an inhibitory signal to limit axonal growth of the neuron. PIR-B deficiency therefore results in axonal growth in an axon injury model. LILRA3 is also involved in axonal growth mechanisms. Soluble LILRA3 promotes neurite outgrowth and synapse formation through interaction with Nogo 66, suggesting that LILRA3 might be a competitive antagonist for these cell surface inhibitory receptors (47) . LILRA3 represents a new antagonist against Nogo66-mediated inhibition of neurite outgrowth in the CNS, a function distinct from its immune-regulatory role in leukocytes.
Alzheimer's disease Alzheimer's disease (AD) is the most common agerelated dementia. The major pathological hallmarks of AD are extracellular amyloid-b (Ab) plaque deposition and intracellular neurofibrillary tangle formations, as well as atrophy of the brain parenchyma caused by neuronal degeneration (48) .
Although the molecular mechanisms of Ab generation and deposition have been well elucidated, the underlying mechanisms of neuronal degeneration in AD brain remain to be clarified. Under physiological conditions, Ab peptides adopt several conformations, such as oligomers. Among these conformations, the severity of AD has been shown to be closely correlated with the concentration of soluble oligomer (Ab42 oligmer), which may trigger neuronal toxicity and cause dementia. One possible reason for this is that the Ab42 oligomer induces a neuronal death signal via its specific receptor (48) .
It was recently shown that murine PIR-B and human LILRB2 are also expressed in CNS neurons and bind to Ab42 oligomer, and the D1 and D2 domains mediate this binding (Fig. 3) . However, there are also undetectable interactions with activation receptor PIR-A, human inhibitory receptor LILRB1 or LILRB3. In addition, the binding of Ab42 oligomer to cortical neurons derived from Pirb -/-mice were reduced by approximately 50% compared with wildtype neurons (49) .
PIR-B is also thought to be involved in AD pathogenesis. Ab42 oligomers attenuated long-term potentiation (LTP) in hippocampal slices from wild-type mice, whereas in Pirb -/-slices, LTP remained intact. PIR-B contributes not only to the Ab-mediated loss of hippocampal LTP but also to defects in recognition memory that characterize older AD model transgenic mice. Furthermore, the interactions between Ab42 oligomers and PIR-B generate not only synaptotoxicity in mouse models of AD but also early defects in developmental plasticity present in the visual cortex. PIR-B therefore may play an important role in age-related hippocampal aging, and the decline in the hippocampal function and aging cause cognitive dysfunction associated with AD.
Conclusion
Inhibitory MHC class I receptors on myeloid cells, such as LILRB1, B2 and PIR-B, interact with a broad range of MHC class I members. Therefore, these receptors do not aim to discriminate between self and non-self but constantly deliver self-regulatory signaling. In contrast, MHC haplotypes are associated with the development of various immune disorders, including allergy and autoimmune diseases. The inhibitory myeloid MHC class I receptors are therefore potential therapeutic targets that overcome MHC haplotype variations.
In addition, LILRBs and PIR-B have been found to be expressed in the CNS and are involved in a major pathological process-the inhibition of axonal regeneration and synaptic plasticity. Similarly to NgR, LILRBs and PIR-B are receptors for MAIs, but their physiological roles remain to be elucidated. Furthermore, the binding of Ab42 oligomers to LILRBs and PIR-B affects the pathogenesis of AD, Role of leukocyte Ig-like receptors suggesting that blocking these receptors might be a new therapeutic strategy for AD.
Several recent studies have shown that MHC class I is involved in neurogenesis and neurodegeneration (50, 51) . Further investigations into these receptors and ligands are needed to elucidate the molecular mechanisms of autoimmune and nervous disorders.
